Biophagy

Executive Summary

Biophagy is a private biopharmaceutical company based in San Francisco, with operations rooted in Albuquerque, NM, focused on developing autophagy-based therapeutics. Founded in 2016, the company aims to strengthen the body's natural defenses against disease and aging through targeted modulation of autophagy. In addition to its drug development pipeline, Biophagy offers CellWatch™, a personalized formulation and diagnostic kit designed to help individuals monitor and enhance their autophagy function. The company operates at the intersection of biologics and small molecules, leveraging autophagy as a broad therapeutic platform for indications spanning neurodegeneration, metabolic disorders, and oncology. As a private entity with limited public disclosure, Biophagy's progress is not widely tracked. The company's lead programs are believed to be in preclinical or early clinical stages, with no disclosed financing rounds or partnerships. The autophagy space is competitive but holds significant promise, and Biophagy's dual approach (therapeutics + diagnostics) could provide a unique competitive advantage if validated. However, the lack of transparent milestones and early-stage risk warrant a conservative outlook. Near-term catalysts may include the initiation of a first-in-human trial, a strategic collaboration, or enhancements to the CellWatch platform.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase I trial for lead autophagy modulator candidate60% success
• Q3 2026Partnership or licensing deal for CellWatch diagnostic platform70% success
• Q1 2027Announcement of research collaboration with academic institution50% success